Lates News

According to AI Express News, Pacific Securities issued a research report on November 6th, giving Chunli Medical (688236.SH) a "buy" rating. The main reasons for the rating include: 1) the impact of centralized procurement is gradually clearing, highlighting profit potential; 2) overseas market access is advancing continuously, demonstrating global competitiveness; 3) gross profit margin is stabilizing, and expense ratio has significantly improved. (Daily Economic News)